Arshad Khanani, MD

Learn how next‑gen anti‑VEGF therapies rapidly control wet AMD, DME and vein occlusion, cutting injections and protecting vision.

How treat-and-extend anti-VEGF care lowers injection burden and reshapes payer access decisions, guided by real-world evidence.

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing cuts clinic burden, affects costs, and reveals key evidence gaps for AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.